A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
← catalyst calendarNCT06742723 · readout in 1,217 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
5,000estimated
Sites
769
Countries
Argentina, Australia, Belgium +39
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-03 | actual | When the study began enrolling |
| Primary completion | 2029-12-18 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-12-18 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Kidney Disease and Hypertension
Interventions
- Drug: Baxdrostat/dapagliflozin — also filed as Baxdrostat CIN-107
- Drug: Placebo/dapagliflozin
Primary outcome
what the primary-completion date above is the date OFTo determine whether baxdrostat/dapagliflozin is superior to placebo/dapagliflozin in reducing the risk of the composite endpoint of ≥ 50% sustained decline in eGFR, kidney failure, Heart Failure events(HF), or CV death.
measured Up to 37 months
Publications
- PMID 42335037 — linked by the registry
- PMID 40913594 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed